Chemical biology-whole genome engineering datasets predict new antibacterial combinations
Open Access
- 7 December 2021
- journal article
- research article
- Published by Microbiology Society in Microbial Genomics
- Vol. 7 (12) , 000718
Abstract
Trimethoprim and sulfamethoxazole are used commonly together as cotrimoxazole for the treatment of urinary tract and other infections. The evolution of resistance to these and other antibacterials threatens therapeutic options for clinicians. We generated and analysed a chemical-biology-whole-genome data set to predict new targets for antibacterial combinations with trimethoprim and sulfamethoxazole. For this we used a large transposon mutant library in Escherichia coli BW25113 where an outward-transcribing inducible promoter was engineered into one end of the transposon. This approach allows regulated expression of adjacent genes in addition to gene inactivation at transposon insertion sites, a methodology that has been called TraDIS-Xpress. These chemical genomic data sets identified mechanisms for both reduced and increased susceptibility to trimethoprim and sulfamethoxazole. The data identified that over-expression of FolA reduced trimethoprim susceptibility, a known mechanism for reduced susceptibility. In addition, transposon insertions into the genes tdk, deoR, ybbC, hha, ldcA, wbbK and waaS increased susceptibility to trimethoprim and likewise for rsmH, fadR, ddlB, nlpI and prc with sulfamethoxazole, while insertions in ispD, uspC, minC, minD, yebK, truD and umpG increased susceptibility to both these antibiotics. Two of these genes’ products, Tdk and IspD, are inhibited by AZT and fosmidomycin respectively, antibiotics that are known to synergise with trimethoprim. Thus, the data identified two known targets and several new target candidates for the development of co-drugs that synergise with trimethoprim, sulfamethoxazole or cotrimoxazole. We demonstrate that the TraDIS-Xpress technology can be used to generate information-rich chemical-genomic data sets that can be used for antibacterial development.Keywords
Funding Information
- Biotechnology and Biological Sciences Research Council (BB/R012504/1)
- Biotechnology and Biological Sciences Research Council (BBS/E/F/000PR10349)
This publication has 35 references indexed in Scilit:
- In Vitro Antimicrobial Resistance of Urinary Escherichia coli Isolates among U.S. Outpatients from 2000 to 2010Antimicrobial Agents and Chemotherapy, 2012
- Artemis: an integrated platform for visualization and analysis of high-throughput sequence-based experimental dataBioinformatics, 2011
- A Second Target of the Antimalarial and Antibacterial Agent Fosmidomycin Revealed by Cellular Metabolic ProfilingBiochemistry, 2011
- Phenotypic Landscape of a Bacterial CellCell, 2011
- Prevalence of trimethoprim resistance genes in Escherichia coli isolates of human and animal origin in LithuaniaJournal of Medical Microbiology, 2010
- Construction of Escherichia coli K‐12 in‐frame, single‐gene knockout mutants: the Keio collectionMolecular Systems Biology, 2006
- Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction NetworksGenome Research, 2003
- Fluoroquinolones in the treatment of acute uncomplicated urinary tract infections in adult womenExpert Opinion on Pharmacotherapy, 2001
- Characterisation of two new gene cassettes,aadA5anddfrA17FEMS Microbiology Letters, 2000
- Massive overproduction of dihydrofolate reductase in bacteria as a response to the use of trimethoprimEuropean Journal of Biochemistry, 1987